Hu3F8 + GM-CSF for Osteosarcoma
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to find out what effect an antibody called Humanized 3F8 (Hu3F8) and a drug called GM-CSF have on the patient and whether it can keep the patient in remission longer and/or prevent recurrence of the disease.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it does mention that at least three weeks should have passed since your last cytotoxic therapy, immunotherapy, or radiation therapy before joining the trial.
Is the treatment Hu3F8 + GM-CSF safe for humans?
How is the drug Hu3F8 + GM-CSF unique for treating osteosarcoma?
The drug Hu3F8 + GM-CSF is unique because it combines a humanized monoclonal antibody (Hu3F8) with GM-CSF, which can enhance the immune system's ability to fight cancer by stimulating certain white blood cells and potentially improving immune responses against tumors. This approach is different from standard chemotherapy as it aims to boost the body's natural defenses to target cancer cells.35678
What data supports the effectiveness of the drug GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) in treating osteosarcoma?
Who Is on the Research Team?
Filemon Dela Cruz, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for people aged 1-40 who have recurrent osteosarcoma and are in at least their second complete remission. They must have normal organ function, no overt metastases, not be pregnant or breastfeeding, and can't have had the study drug before. Participants need to agree to use birth control and should not have a life-threatening infection.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive hu3F8 and GM-CSF over a cycle of 10 days, repeated every 2-4 weeks for up to 5 cycles
Follow-up
Participants are monitored for event-free survival and time to recurrence
What Are the Treatments Tested in This Trial?
Interventions
- GM-CSF
- Humanized Monoclonal Antibody 3F8 (Hu3F8)
GM-CSF is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Children's Hospital Los Angeles
Collaborator
M.D. Anderson Cancer Center
Collaborator
Y-mAbs Therapeutics
Industry Sponsor